

# Review of: "Risk of death derived from Hazard Ratio should not be communicated as Relative Risk reductions for death in cancer clinical trials. Intentional or inadvertent?"

Riccardo Ray Colciago

Potential competing interests: No potential competing interests to declare.

Dear colleagues,

I want to express my gratitude for your hard work.

While recognizing the pivotal importance of Absolute Risk and Number Needed to Treat in prescribing costly therapies, it's crucial to note that this paper primarily presents a critical review of studies related to cervical cancer, rather than yielding methodologically stringent results.

I propose that we consider adjusting the title to explicitly reflect the focus on cervical cancer within this paper.

Thank you for your dedication and commitment.